Literature DB >> 1677765

Clozapine.

M W Jann1.   

Abstract

Clozapine is a neuroleptic agent whose structure consists of a dibenzodiazepine derivative with a piperazinyl side chain. It has been classified as an atypical neuroleptic drug due to its unique neuropharmacologic profile. Clozapine has a weak binding affinity for dopamine D-1 and D-2 receptors by its slightly greater preference for D-1 receptors, as noted with a D-1:D-2 receptor binding ratio of 1.3. Other neuroreceptors are involved, as the drug has potent binding affinity for serotonin receptors 5-HT1A and 5-HT2. Clozapine also has antihistaminic, anticholinergic, and alpha-adrenergic antagonistic properties. Electrophysiologic studies show that it differs from other typical neuroleptics in that its actions appear to be specific for the cortical-limbic dopamine A-10 tract. In animal paradigms, in contrast to typical neuroleptics, clozapine did not produce catalepsy and had only transient effects in antagonizing other dopamine agonists. The drug is rapidly absorbed orally with a bioavailability of 0.27. After a single oral dose the elimination half-life was approximately 8-10 hours, but with several doses it increased to 14.1 hours. The agent is extensively metabolized by hepatic microsomal enzymes that forms the N-desmethyl and N-oxide metabolites. It is an effective neuroleptic that has been studied in short-term and long-term clinical trials, and multicenter trials. Clozapine was superior to chlorpromazine in the treatment of refractory schizophrenia that failed to respond to previous neuroleptic therapy. Reports of extrapyramidal side effects are minimal, and no case reports of tardive dyskinesia have been published. Indeed, clozapine has been used to treat tardive dyskinesia and other movement disorders. Agranulocytosis is the major adverse effect and its prevalence appears to differ among various ethnic groups. Other adverse effects that have been reported include hypersalivation, orthostatic hypotension, and constipation. Clozapine can lower the seizure threshold in a dose-dependent manner. The drug represents a significant advancement in the treatment of mental illness.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677765

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  16 in total

Review 1.  Effects of antipsychotics on the unborn child: what is known and how should this influence prescribing?

Authors:  H B Pinkofsky
Journal:  Paediatr Drugs       Date:  2000 Mar-Apr       Impact factor: 3.022

Review 2.  Dopamine receptor genes: new tools for molecular psychiatry.

Authors:  H B Niznik; H H Van Tol
Journal:  J Psychiatry Neurosci       Date:  1992-10       Impact factor: 6.186

3.  Analysis of genetic variations in the dopamine D1 receptor (DRD1) gene and antipsychotics-induced tardive dyskinesia in schizophrenia.

Authors:  I-Ching Lai; Geng-Han Mo; Mao-Liang Chen; Ying-Chieh Wang; Jen-Yeu Chen; Ding-Lieh Liao; Ya-Mei Bai; Chao-Cheng Lin; Tzu-Ting Chen; Ying-Jay Liou
Journal:  Eur J Clin Pharmacol       Date:  2010-12-22       Impact factor: 2.953

Review 4.  Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders.

Authors:  Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2006-10       Impact factor: 5.590

5.  The effect of clozapine on self-injurious behavior.

Authors:  R G Hammock; S R Schroeder; W R Levine
Journal:  J Autism Dev Disord       Date:  1995-12

6.  Telescoped synthesis of C3-functionalized (E)-arylamidines using Ugi-Mumm and regiospecific quinazolinone rearrangements.

Authors:  Victor A Jaffett; Alok Nerurkar; Xufeng Cao; Ilia A Guzei; Jennifer E Golden
Journal:  Org Biomol Chem       Date:  2019-03-20       Impact factor: 3.876

Review 7.  The neurobiology of apolipoproteins in psychiatric disorders.

Authors:  J Gregor Sutcliffe; Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

8.  Clozapine's functional mesolimbic selectivity is not duplicated by the addition of anticholinergic action to haloperidol: a brain stimulation study in the rat.

Authors:  E L Gardner; L S Walker; W Paredes
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  Pharmacokinetics and pharmacodynamics of clozapine.

Authors:  M W Jann; S R Grimsley; E C Gray; W H Chang
Journal:  Clin Pharmacokinet       Date:  1993-02       Impact factor: 6.447

Review 10.  The role of active metabolites in drug toxicity.

Authors:  M Pirmohamed; N R Kitteringham; B K Park
Journal:  Drug Saf       Date:  1994-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.